XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Passes Above Fifty Day Moving Average – What’s Next?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.57 and traded as high as $2.89. XTL Biopharmaceuticals shares last traded at $2.89, with a volume of 7,504 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

XTL Biopharmaceuticals Stock Up 1.8%

The stock has a market cap of $6.36 million, a P/E ratio of -4.52 and a beta of 1.45. The business has a 50 day moving average price of $2.57 and a 200 day moving average price of $2.86.

XTL Biopharmaceuticals (NASDAQ:XTLB) last posted its quarterly earnings data on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of ($0.26) million during the quarter.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.